Next Investors logo grey

Regeneus surges on back of Progenza patent news

Published 23-MAR-2020 12:13 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Clinical-stage regenerative medicine company Regeneus Ltd (ASX: RGS) announced on Monday morning that the US Patent and Trademark Office (USPTO) had issued a notice of allowance for issuance of a new key patent for the company’s lead stem cell platform technology Progenza.

This paves the way for the issue of a patent that would be applicable in the US.

Highlighting what a major development this is for Regeneus, the group’s shares were up more than 10% despite the S&P/ASX All Ordinaries (XAO) being down more than 400 points.

It has been an exciting month for the company as this comes on the back of a non-refundable milestone payment of approximately $1.6 million from Kyocera Corporation (TYO:6971).

This payment was made under the terms of a non-binding memorandum of understanding negotiated with Kyocera at the start of the month providing the latter with exclusive negotiation rights to the Progenza platform technology for the treatment of knee osteoarthritis in Japan.

The new patent to be granted in the US covers the treatment of inflammatory conditions with the combination of stem cells and secretions.

This includes inflammatory conditions caused by a wide range of diseases, such as arthritis, heart disease, autoimmune conditions, respiratory diseases, asthma, Crohn's disease and other gastrointestinal diseases.


Patent also covers Acute Respiratory Distress Syndrome

The patent to be granted for Progenza also covers Acute Respiratory Distress Syndrome (ARDS), an inflammatory lung condition identified as a cause of death among patients diagnosed with COVID-19.

The success of Progenza on this front was recently documented in Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

ARDS is also a common cause of respiratory failure in critically ill patients.

Unlike pneumonia, there is no pharmaceutical treatment for ARDS23.

Notwithstanding the potential applications outside its core markets, Regeneus chief executive and executive director Leo Lee said, “While Regeneus’ focus remains on osteoarthritis and pain opportunities, this is a key patent which strengthens our intellectual property portfolio.

‘’It also opens doors to form partnerships for Progenza for other disease and indications.”

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.